Antibodies Contract Manufacturing Market Size & Growth Analysis to 2030

The global antibodies contract manufacturing market size is anticipated to register a higher CAGR of around 13% during the forecast period 2022 to 2028. The increasing use of antibody therapeutics to treat various diseases such as chronic diseases, cancer, arthritis, and autoimmune diseases is a primary factor to drive the market growth. Furthermore, the increasing focus of biotechnology and biopharmaceutical companies to produce antibody therapeutics and the increasing investment in research & development by private and public organizations are further anticipated to fuel the demand for antibody contract manufacturing over the forecast period. In addition, the use of monoclonal antibody therapy to treat COVID-19 patients is projected to increase the demand for antibody contract manufacturing.

Market Snapshot:

Increasing Demand for Biologic Therapeutics: The growing demand for biologic therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies, drives the need for antibodies contract manufacturing. Biologic therapeutics offer targeted and personalized treatment options for various diseases, such as cancer, autoimmune disorders, and infectious diseases. Contract manufacturing organizations (CMOs) play a crucial role in providing manufacturing capabilities and expertise to meet the demand for biologics.

Complex Manufacturing Processes: The production of antibodies and biologic therapeutics involves complex manufacturing processes, including cell culture, fermentation, purification, and formulation. Establishing and maintaining in-house manufacturing capabilities for these processes can be expensive and time-consuming for pharmaceutical and biotechnology companies. Contract manufacturing provides a cost-effective and efficient solution, enabling companies to focus on research, development, and commercialization.

Capacity Constraints and Time-to-Market Pressure: Pharmaceutical companies often face capacity constraints and time-to-market pressures when developing and commercializing biologic therapeutics. Antibodies contract manufacturing offers additional manufacturing capacity and flexibility, allowing companies to scale up production and accelerate time-to-market for their products. Contract manufacturing helps meet the demand for biologics while reducing time and resource constraints.

Cost Reduction and Efficiency: Outsourcing antibody manufacturing to contract manufacturing organizations can help pharmaceutical companies reduce manufacturing costs and improve efficiency. CMOs specialize in manufacturing processes, have optimized infrastructure, and can achieve economies of scale. By leveraging the expertise and infrastructure of CMOs, companies can reduce manufacturing costs and improve the cost-effectiveness of their biologic therapeutics.

Regulatory Expertise and Compliance: The antibodies contract manufacturing market is driven by the need for regulatory expertise and compliance. Manufacturing biologic therapeutics involves strict regulatory requirements and compliance with Good Manufacturing Practices (GMP) and other quality standards. Contract manufacturing organizations have experience and expertise in navigating regulatory processes, ensuring compliance, and meeting the quality standards set by regulatory authorities.

Focus on Core Competencies: Contract manufacturing allows pharmaceutical companies to focus on their core competencies, such as research, development, and commercialization, while outsourcing manufacturing to specialized CMOs. By partnering with CMOs, companies can leverage the manufacturing expertise of CMOs and concentrate their resources and efforts on their core areas of expertise.

Flexibility and Scalability: The antibodies contract manufacturing market provides flexibility and scalability to accommodate fluctuations in demand and varying manufacturing needs. Companies may require increased manufacturing capacity for clinical trials, product launches, or market expansions. Contract manufacturing offers the flexibility to scale up or down production as needed, providing cost-effective and efficient manufacturing solutions.

Emerging Biotechnology and Biopharmaceutical Companies: The growth of emerging biotechnology and biopharmaceutical companies contributes to the demand for antibodies contract manufacturing. These companies often lack the infrastructure, resources, and expertise to establish in-house manufacturing capabilities. Contract manufacturing allows them to access manufacturing capabilities, reduce upfront investments, and accelerate the development and commercialization of their biologic therapeutics.

Technological Advancements: Technological advancements in biomanufacturing, such as single-use technologies, process automation, and continuous manufacturing, impact the antibodies contract manufacturing market. These advancements improve manufacturing efficiency, reduce production costs, and enhance product quality. Contract manufacturing organizations that adopt and incorporate these technologies into their processes can provide advanced manufacturing solutions to their clients.

Market Drivers:

Increasing Demand for Biologic Therapeutics: The growing demand for biologic therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies, drives the need for antibodies contract manufacturing. Biologic therapeutics offer targeted and personalized treatment options for various diseases, such as cancer, autoimmune disorders, and infectious diseases. Contract manufacturing organizations (CMOs) play a crucial role in providing manufacturing capabilities and expertise to meet the demand for biologics.

Complex Manufacturing Processes: The production of antibodies and biologic therapeutics involves complex manufacturing processes, including cell culture, fermentation, purification, and formulation. Establishing and maintaining in-house manufacturing capabilities for these processes can be expensive and time-consuming for pharmaceutical and biotechnology companies. Contract manufacturing provides a cost-effective and efficient solution, enabling companies to focus on research, development, and commercialization.

Capacity Constraints and Time-to-Market Pressure: Pharmaceutical companies often face capacity constraints and time-to-market pressures when developing and commercializing biologic therapeutics. Antibodies contract manufacturing offers additional manufacturing capacity and flexibility, allowing companies to scale up production and accelerate time-to-market for their products. Contract manufacturing helps meet the demand for biologics while reducing time and resource constraints.

Cost Reduction and Efficiency: Outsourcing antibody manufacturing to contract manufacturing organizations can help pharmaceutical companies reduce manufacturing costs and improve efficiency. CMOs specialize in manufacturing processes, have optimized infrastructure, and can achieve economies of scale. By leveraging the expertise and infrastructure of CMOs, companies can reduce manufacturing costs and improve the cost-effectiveness of their biologic therapeutics.

Regulatory Expertise and Compliance: The antibodies contract manufacturing market is driven by the need for regulatory expertise and compliance. Manufacturing biologic therapeutics involves strict regulatory requirements and compliance with Good Manufacturing Practices (GMP) and other quality standards. Contract manufacturing organizations have experience and expertise in navigating regulatory processes, ensuring compliance, and meeting the quality standards set by regulatory authorities.

Focus on Core Competencies: Contract manufacturing allows pharmaceutical companies to focus on their core competencies, such as research, development, and commercialization, while outsourcing manufacturing to specialized CMOs. By partnering with CMOs, companies can leverage the manufacturing expertise of CMOs and concentrate their resources and efforts on their core areas of expertise.

Flexibility and Scalability: The antibodies contract manufacturing market provides flexibility and scalability to accommodate fluctuations in demand and varying manufacturing needs. Companies may require increased manufacturing capacity for clinical trials, product launches, or market expansions. Contract manufacturing offers the flexibility to scale up or down production as needed, providing cost-effective and efficient manufacturing solutions.

Emerging Biotechnology and Biopharmaceutical Companies: The growth of emerging biotechnology and biopharmaceutical companies contributes to the demand for antibodies contract manufacturing. These companies often lack the infrastructure, resources, and expertise to establish in-house manufacturing capabilities. Contract manufacturing allows them to access manufacturing capabilities, reduce upfront investments, and accelerate the development and commercialization of their biologic therapeutics.

Technological Advancements: Technological advancements in biomanufacturing, such as single-use technologies, process automation, and continuous manufacturing, impact the antibodies contract manufacturing market. These advancements improve manufacturing efficiency, reduce production costs, and enhance product quality. Contract manufacturing organizations that adopt and incorporate these technologies into their processes can provide advanced manufacturing solutions to their clients.

Market Snapshot:

Market Insights:

The global antibodies contract manufacturing market is bifurcated into product, source, end-user, and geography. On the basis of product, the market is further segmented into monoclonal, polyclonal, and other antibodies. The monoclonal antibodies segment dominated the global market in 2021 and is estimated to hold the largest revenue share of over two-thirds market share by the end of the analysis period. the increasing use of the therapy in various lung indications such as asthma, lung cancer, and lung infections is a major factor to drive the segment growth. Furthermore, the growing awareness of monoclonal antibody therapy among patients and physicians is further anticipated to fuel the segment growth over the forecast period.

On the basis of end-user, the market is further segmented into biopharmaceutical companies, research laboratories, and others. The biopharmaceutical companies segment dominated the global antibodies contract manufacturing market in 2021 and is expected to hold the largest share of over two-third market share by the end of the analysis period. The rising prevalence of chronic diseases, the growing geriatric population, and the increasing adoption of technology are some of the major factors to drive the segment growth. Furthermore, the growing use of monoclonal antibody therapy and the increasing investment in research and development are further anticipated to uplift the segment growth over the forecast period.

To know more about the study, request a report sample

The antibodies contract manufacturing comprehensive study analyzes industry trends, market size, competitive analysis, and market forecast – 2022 to 2028. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

The antibodies contract manufacturing market research report presents the analysis of each segment from 2019 to 2028 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

• 2019-20 – Historical Year
• 2021 – Base Year
• 2022-2028 – Forecast Period

Market Segmentation:

By Product:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Others

By Source:

• Mammalian
• Microbial

By End-User:

• Biopharmaceutical Companies
• Research Laboratories
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis:

Geographically, North America dominated the global antibodies contract manufacturing market in 2021 and expected to hold the largest market share of over one-third share by the end of the analysis period. The large-scale manufacturing of biopharmaceuticals is a key factor to drive the market growth in the region. Furthermore, the increasing number of clinical trials, well-structured healthcare facilities, and the increasing investment in research and development are further anticipated to boost the market growth in North America. On the other hand, the Asia Pacific is expected to register the highest growth rate over the forecast period.

Competitive Assessment:

Some of the major market players operating in the global antibodies contract manufacturing market are AGC Biologics, Samsung Biologics, Lonza, Charles River Laboratories, and WuXi Biologics. Companies are exploring markets through expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• AGC Biologics
• Samsung Biologics
• Lonza
• Charles River Laboratories
• WuXi Biologics
• FUJIFILM Holdings Corporation
• AGC Biologics
• Boehringer Ingelheim Biopharmaceuticals GmbH
• EMERGENT
• Cytovance Biologics, Inc.
• Thermo Fisher Scientific

Key Questions Answered by Antibodies Contract Manufacturing Market Report

• Global antibodies contract manufacturing market forecasts from 2022-2028
• Regional market forecasts from 2022-2028 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2022-2028 covering 15 major countries from the regions as mentioned above
• Antibodies contract manufacturing submarket forecasts from 2022-2028 covering the market by product, by source, by end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level antibodies contract manufacturing markets from 2022-2028
• Competitive Landscape and market positioning of top 10 players operating in the market